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Background: In 2007 the St. Gallen consensus panel deﬁned three endocrine response classes: highly
endocrine responsive (ER-H), incomplete endocrine responsive (ER-I) and non-endocrine responsive
tumours (ER-N). However, it is uncertain whether ER-I tumours are less responsive than ER-H tumours.
We investigated whether recurrence rates vary over time between response classes. Additionally, we
investigated the most predictive response class deﬁnition for tamoxifen beneﬁt.
Patients and methods: We recollected tumours from 646 patients who participated in a randomized trial
of adjuvant tamoxifen vs. observation. Estrogen receptor (ER), progesterone receptor (PgR), HER2 status
and tumour grade were revised centrally. St. Gallen classes were evaluated for recurrence free interval
(RFI). Change in hazards over time was assessed. Subsequently, 6 alternative response class deﬁnitions
were compared to optimize the cut-off for PgR and ER.
Results: Schoenfeld residuals indicate a failure of proportional hazards between the endocrine response
groups (p ¼ 0.0001). The HR for recurrence risk shifted over time with the ER-H group initially being at
lower risk (HR ER-H vs. ER-I 0.5), but after six years the recurrence risk increased (HR 1.9). The cut-off
values for ER and PgR that statistically best discriminated RFI in the ﬁrst 4 years for lymph node posi-
tive patients were ER  50% and PgR  75%.
Conclusion: We demonstrated a marked variability in endocrine therapy beneﬁt. Patients with ER-H
tumours have a larger beneﬁt during adjuvant tamoxifen and in the ﬁrst years after accomplishing of
the therapy, but suffer from late recurrences. This might have implications for optimal treatment
duration.
© 2015 Elsevier Ltd. All rights reserved.Background
Estrogen receptor (ER) positive breast cancer patients are
generally recommended adjuvant endocrine therapy. Although
recurrence rates and mortality have decreased substantially, still
more than 30% of these patients relapse [1].
While predictive biomarkers in breast cancer are studiedwidely,
ER is still the most powerful individual predictor of beneﬁt from
endocrine therapy [2]. However many questions concerningte, Plesmanlaan 121, 1066 CX
fax: þ31 20 5122572.
ra).technique and scoring of ER are still unanswered. Already in 1999
Harvey et al. described and validated a composite score (a combi-
nation of intensity and percentage of positive staining invasive
cells) of immunohistochemistry (IHC) staining for ER in breast
cancer [3]. However currently, with automated staining, over-
saturated conditions to allow rapid reaction (about 30 min or less)
for antibodyeantigen binding lead to oversaturation on intensity.
Therefore, in the 2010 ASCO pathology guidelines on ER testing the
need and utility to report composite scores (e.g. H-score, Allred, or
quick score) is questioned [4].
Furthermore, the cut-off of positive staining cells varies greatly.
In the clinical guidelines the hormone receptor (HR) status is
assessed as a dichotomous variable with a tumour considered
hormone receptor positive when 1% of the invasive cells stain
Table 1
Patient characteristics vs. St. Gallen response groups.
ER-N ER-I ER-H All p-value
N ¼ 135 N ¼ 329 N ¼ 182 N ¼ 646
Age
Median 62 66 65 65
(Range) (47e78) (45e80) (49e77) (45e80) 0.04
Treatment
No Tamoxifen 36 (27%) 74 (22%) 43 (24%) 153 (24%)
Tamoxifen 99 (73%) 255 (78%) 139 (76%) 493 (76%) 0.58
Tamoxifen duration (mths)
Median 14 13 14 13
(Range) (0.8e76) (0.1e59) (0.2e76) (0.1e76)
Nodal status
Nþ 74 (55%) 156 (47%) 78 (43%) 308 (48%)
N 61 (45%) 173 (53%) 104 (57%) 338 (52%) 0.04
ER (cut-off 1%)
0% 135 (100%) 9 (3%) 0 (0%) 144 (22%)
1e100% 0 (0%) 320 (97%) 182 (100%) 502 (78%)
ER (St. Gallen crit.)
0% 135 (100%) 9 (3%) 0 (0%) 144 (22%)
1e50% 0 (0%) 27 (8%) 0 (0%) 27 (4%)
>50% 0 (0%) 293 (89%) 182 (100%) 475 (74%)
PgR (cut-off 1%)
0% 135 (100%) 200 (61%) 0 (0%) 335 (52%)
1e100% 0 (0%) 129 (39%) 182 (100%) 311 (48%)
PgR (St. Gallen crit.)
0% 135 (100%) 200 (61%) 0 (0%) 335 (52%)
1e50% 0 (0%) 122 (37%) 0 (0%) 122 (19%)
>50% 0 7 (2%) 182 (100%) 189 (29%)
HER2
Negative 95 (70%) 277 (84%) 169 (93%) 541 (84%)
Positive 36 (27%) 38 (12%) 6 (3%) 80 (12%)
Unknown 4 (3%) 14 (4%) 7 (4%) 25 (4%) <0.0001
T-stage (clinical)
T1 32 (24%) 104 (32%) 47 (26%) 183 (28%)
T2 84 (62%) 186 (57%) 114 (63%) 384 (59%)
T3 12 (9%) 25 (8%) 16 (9%) 53 (8%)
T4 5 (4%) 10 (3%) 5 (3%) 20 (3%)
Unknown 2 (1%) 4 (1%) 0 (0%) 6 (<1%) 0.74
Grade
1 4 (3%) 72 (22%) 57 (31%) 133 (21%)
2 33 (24%) 119 (36%) 81 (45%) 233 (36%)
3 98 (73%) 138 (42%) 44 (24%) 280 (43%) <0.0001
ER-H ¼ highly endocrine responsive patients; ER-I ¼ incomplete endocrine
responsive patients; ER-N ¼ non-endocrine responsive patients.
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clinical practice, a range of thresholds is used, varying from 1% to
10%. However prospective data addressing the optimal cutoff level
correlated with the efﬁcacy of endocrine treatment are lacking. In
retrospective studies survival rates of patients with tumours
expressing ER in 1e9% did not signiﬁcantly differ from patients
with ER <1% tumours [8]. In molecular subtyping studies most
tumours expressing ER 1e9% show ER, basal-like molecular
characteristics [9]. Additionally, while the incidence of low ER score
(1e9%) is only approximately 1% [10], this represents a very little
clinical problem. In the Netherlands the cut-off to consider a
tumour HRþ is deﬁned at 10% of invasive cells staining positive [11].
A positive hormone receptor status is considered sufﬁcient to
justify 5 years of adjuvant endocrine therapy [12]. However, this
completely disregards the potential variance in treatment sensi-
tivity of individual HRþ tumours.
In current clinical practice, several decision aids are being
developed. For example the 21-gene recurrence score has been
shown to predict distant recurrence in tamoxifen-treated patients
[13]. Since ER, PgR and HER2 are major components of gene-
expressing based assays, it might be speculated that standardized,
quality-controlled pathological tests may have a similar predictive
power. Actually, Allison et al. showed that features like PgR, grade
and Ki67 can predict recurrence score in a subset of ERþ patients
[14]. Whether or not the combined analysis of precise percentages
of receptor expression levels can also predict beneﬁt from endo-
crine therapy is unknown.
Already in 2007 the St. Gallen consensus panel deﬁned three
endocrine response classes for decision making on adjuvant
endocrine and chemotherapeutic treatment [15e17]. It is accepted
to deﬁne the St. Gallen classes as follows: tumours lacking both ER
and PgR (using a cut-off of 1% of positive nuclei) are “non endo-
crine-responsive” (ER-N); tumours expressing both ER and PgR in
50% or more of the tumour cells are “highly endocrine responsive”
(ER-H); all others are “incomplete endocrine responsive” (ER-I)
[18,19]. However, validation of these deﬁnitions is lacking [18]. And
though its nomenclature suggests this, it is not clear whether ER-I
tumours are less endocrine responsive than ER-H tumours. In a
recent publication, Dowsett et al. demonstrated, that ER mRNA
expression levels are positively correlated with tamoxifen beneﬁt
[20]. We investigated whether there is a difference in treatment
beneﬁt and whether there are differences in treatment beneﬁt over
time based on St. Gallen classes, deﬁned with IHC. Furthermore we
investigated the optimal cut-off values for deﬁning the response
classes.
Methods
Patients and material
We recollected primary tumours from stage IeIII post-
menopausal breast cancer patients from the IKA tamoxifen trial
(IKA trial, 1982e1994). Patients were randomized (2:1) between
one year tamoxifen (30 mg per day) versus no adjuvant therapy,
followed by a second randomization, after one year, for the
tamoxifen treated patients to receive another two years of
tamoxifen or to stop further treatment. Patients were eligible if
they were postmenopausal, less than 76 years of age and had a
T1e4, N0e3, M0 breast tumour [21] but no mastitis or palpable
supra- or infraclavicular lymph nodes. From 1989, based on two
interim analyses showing a signiﬁcant improvement in recurrence
free survival in node positive patients, these patients skipped the
ﬁrst randomization and all received 1 year of tamoxifen. Eventu-
ally 1662 patients were enrolled with a 3:1 distribution (tamox-
ifen vs. no treatment), and none received adjuvant chemotherapy.The study data and patient characteristics of the original study
group [22] and different subgroups have been presented else-
where [23e26]. The data were also part of the Oxford systematic
review [1].
The central ethics committee of the Netherlands Cancer Insti-
tute approved the original trial. Informed consent was obtained
from all study participants. For this retrospective study, no addi-
tional consent was required according to the Dutch Act on medical
research involving humans, and in compliance with Good Clinical
Practice guidelines [27] since archival pathology left-over material
handling does not interfere with patient care. Tumour tissue was
used according to the code of conduct of HumanTissue andMedical
Research: Code of conduct for responsible use (2011)” by the Federa
(http://www.federa.org/codes conduct).Pathology
Tissue blocks from 739 participating patients could be traced.
After construction of a tissue microarray (TMA), 646 tumours were
left with sufﬁcient material for both ER, PgR and HER2 analysis.
Median follow-up of this series for RFI is 9.56 years (95%CI:
9.14e9.90). Median follow-up for overall survival is 13.2 years (95%
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current analysis see Table 1.
One observer (PJvD) centrally revised all tumours. TMAs were
stained for ER, PgR and HER2. The percentage of positive nuclei
was scored for ER and PgR. HER2 was considered positive when
membranous staining was DAKO score 3. In case of a DAKO score 2,
Silver In Situ Hybridization was performed using UltraView SISH
Detection Kit (Ventana®) according to the manufacturer's
instructions.
In order to identify the optimal cut-off values for deﬁning the
response classes, we predeﬁned six possible deﬁnitions of cut-off
values for ER and PgR to compare. Deﬁnition 1: ER  50% &
PgR 75%; deﬁnition 2: ER 50%& PgR 50% (current deﬁnition);
deﬁnition 3: ER  50% & PgR  25%; deﬁnition 4: ER  75%; deﬁ-
nition 5: ER  50%; deﬁnition 6: ER  25%.Statistical methods
The associations between endocrine response groups and grade,
tumour stage, nodal stage and HER2 status were tested using
linear-by-linear tests. The association between ER  50% and
PgR  50% was tested using a Fisher exact test. Recurrence free
interval (RFI) was deﬁned as the time from the ﬁrst randomization
until the occurrence of a local, regional or distant recurrence or
breast cancer speciﬁc death [28]. Effect of tamoxifen treatment was
assessed using Cox proportional hazard models. Due to the change
in randomization of the original trial analyses are stratiﬁed by
nodal status, where appropriate.
Multivariable Cox regressions include tumour grade, T-stage,
HER2 status and age as covariates. The proportional hazards
assumption was tested using the Schoenfeld's partial residuals
technique [29]. The assessment of hazard ratios during particular
periods (e.g., 0e2, 2e4, 4e6 and >6 years) were assessed using
landmark analyses including patients who were event free at the
start of each period, and being censored at the end of each period.
The model log-likelihood chi-squares and concordance indices
were used to determine the best-predictive endocrine response
deﬁnition using differing ER and PgR thresholds. RFI curves were
constructed using the KaplaneMeier method. All analyses were
performed using R (v3.0.1).Results
Endocrine response groups correlate with grade and HER2
ER-N patients (N ¼ 135, 21%) did not exhibit signiﬁcant beneﬁt
from tamoxifen (multivariable HR ¼ 0.8 (0.4e1.5)) and were
excluded from further analyses. 329 tumours were classiﬁed as ER-I
(51%) and 182 tumours were classiﬁed as ER-H (28%). ER-I tumours
were more often HER2 positive (p < 0.0001) and were associated
with higher tumour grade (p < 0.0001).Overall tamoxifen beneﬁt in ER positive patients
In this representative subset (n ¼ 511) of the total study popu-
lation, the multivariable recurrence free interval hazard ratio (HR)
for tamoxifen in ERþ patients was 0.3 (95%CI 0.2e0.6; p ¼ 0.003)
for lymph node positive patients and 0.7 (95%CI 0.4e1.4; p ¼ 0.36)
for lymph node negative patients. When stratiﬁed by nodal status,
the tamoxifen effect in ERþ patients was 0.5 (95% CI 0.3e0.8,
p ¼ 0.002). The median duration of tamoxifen treatment was 13
months (range 0.1e76 months).Hazard ratios for recurrence vary over time
Examination of Schoenfelds partial residuals indicated a failure
of proportional hazards for recurrence between the ER-H and ER-I
groups (p ¼ 0.0001). Fig. 1a presents the univariate KaplaneMeier
curves for the three endocrine response groups, both treated versus
untreated and nodal positive versus negative. The RFI-curves for
the ER-H group exhibit a decline after approximately six years. In
Fig.1b the time periods are separated in two periods (0e5 years and
5 year-later) in order to visualize the effect of the non-proportional
hazards more clearly. However, since these are univariate curves
one should be careful for over-interpretation of the curves only and
focus more on adjusted hazard ratios. The failure of proportional
hazards was still present after the inclusion of tumour grade, T-
stage, HER2 status, age and the pairwise treatment-St. Gallen class
interaction (p ¼ 0.0003). Landmark analyses for the hazard ratios
for recurrence risk during different time periods illustrate this shift
in recurrence risk. The ER-N group was initially at higher risk for
recurrence when compared with the ER-I group, however this
increased risk faded over time. Even more striking was the differ-
ence between the ER-H and ER-I group over time, with the ER-H
group initially at lower risk (HR 0.5), but over time the recurrence
risk increased (HR 1.9) (Table 2a). Restricting the analysis to Nþ
patients did not affect this result (Table 2b). This increased risk over
time is also reﬂected in approaching KaplaneMeier curves for OS in
tamoxifen treated patients (Fig. S1).Reﬁning the St. Gallen response class deﬁnitions: best predicting
tamoxifen beneﬁt
For testing 6 alternative receptor level cut-off deﬁnitions, best
discriminating tamoxifen beneﬁt, we restricted the analysis to the
tamoxifen treated ER-H and ER-I Nþ patients (according to the
protocol amendment in 1989, identifying those patients at highest
risk) noting that ER and PgR levels were not independent
(p < 0.0001, Fig. 2). We censored at four years in order to prevent
dilution of the treatment effect in time. With this restriction we
found the most pronounced separation between the ER-I and the
ER-H patients concerning RFI to be with ER  50 & PgR  75
(deﬁnition 1) (Chi sq ¼ 3.27, p ¼ 0.07, C-index 0.682; Table 3). This
deﬁnition also provided the most pronounced separation of the
survival curves for the following years (also see Table 4 and Fig. S2).Discussion
Our results indicate that, although high levels of hormone re-
ceptors are associatedwith tamoxifen beneﬁt during treatment and
in the ﬁrst years after accomplishing therapy, after this period, the
recurrence risk for patients with ER-H tumours exceeded that of
patients with ER-I tumours.
Generally, it is known that HRþ breast cancer has a propensity
for late recurrences. More than half of all disease recurrences in
ERþ breast cancer occur 6 years or more after diagnosis, particu-
larly following 5 years of adjuvant anti-estrogen therapy [1,30]. In
several studies it has been shown that HRþ tumours have better
prognosis during the ﬁrst years of follow up and subsequently
showing late recurrences, while in HR-tumours the mortality rate
and relapse rate are initially high and then progressively level off
over time [31e33].
The increased rate of late recurrences in ERþ breast cancer is a
well-known, signiﬁcant clinical challenge. However, little attention
has been paid to non-proportional hazards when analysing the
differences in recurrence risk for HRþ breast cancer patients ac-
cording to their receptor levels.
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Fig. 1. a: KaplaneMeier curves (RFI) for the three endocrine response groups, both treated vs. untreated and nodal positive vs. negative (RFI ¼ relapse free interval;
Tam ¼ tamoxifen treated; Con ¼ control group, untreated patients; Nþ ¼ lymph node positive disease; N ¼ lymph node negative disease; ER-H ¼ highly endocrine responsive
patients; ER-I ¼ incomplete endocrine responsive patients; ER-N ¼ non-endocrine responsive patients). b: KaplaneMeier curves (RFI), same as Fig. a, now separated in two time
periods. Left panel: 0e5 years. Right panel: 5e12 years (100% is deﬁned as all patients without recurrence at 5 years followup).
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Table 2a
Landmark analyses hazard ratios (90% conﬁdence intervals) for the Cox proportional
hazard models including St. Gallen groups and treatment, tumour grade, HER2
status and age and stratifying for nodal status. Time is divided into four period,
patients are only included in a section if they are recurrence free at the start of that
period, and patients without events are censored at the end of each period.
0e2 years 2e4 years 4e6 years 6þ years
ER-N vs. ER-I 3.3 (2e5.2) 1.9 (1.1e3.2) 1.6 (0.7e3.6) 1.1 (0.5e2.7)
ER-H vs. ER-I 0.5 (0.2e1.1) 1.1 (0.7e1.9) 1.3 (0.6e2.8) 1.9 (1e3.6)
Tam vs. Con 0.7 (0.4e1.1) 0.7 (0.4e1.1) 0.2 (0.1e0.3) 1.8 (0.6e5.1)
Table 2b
Sensitivity analysis, same as in Table 2a, however restricted to only Nþ patients.
0e2 years 2e4 years 4e6 years 6þ years
ER-N vs. ER-I 2.8 (1.6e4.7) 2 (1e3.9) 1 (0.3e3.3) 2.4 (0.9e6.3)
ER-H vs. ER-I 0.5 (0.2e1.2) 1.5 (0.8e2.8) 1 (0.3e3.2) 2.4 (1.1e5.3)
Tam vs. Con 0.5 (0.3e0.9) 0.5 (0.3e1.1) 0.2 (0.1e0.6) 2.7 (0.5e15.4)
ER-H ¼ highly endocrine responsive patients; ER-I ¼ incomplete endocrine
responsive patients; ER-N ¼ non-endocrine responsive patients.
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levels are contradictory, leading to a comprehensive discussion
concerning prognostic versus predictive value of ER and PgR
expression. Tovey et al. found favourable outcome for tamoxifen
treated PgRþ patients, compared to PgR patients, during the ﬁrst
years after diagnosis with an increased risk after 3 years of
tamoxifen [34], which is in accordance with our results. However
the data from the Oxford systematic review showed that the overall
beneﬁt from 5 years tamoxifen was not different between ERþ
patients with PgRþ versus PgR tumours [30]. These contradictory
results are possibly confounded by adjuvant chemotherapy beneﬁt,
since Tovey et al. do not report on the percentage of patients
receiving adjuvant chemotherapy. In our current series, patients
received no adjuvant chemotherapy, whereby our results might be0 20 40 60 80 100
0
20
40
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10
0
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P
gR
50 %
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75 %25 %
25 %
Fig. 2. ER vs. PgR status. Blue dots are ER-I and red dots are ER-H patients using the
current deﬁnition. Green dotted lines are indicating the different cut-off values as
discussed in the section on alternative deﬁnitions of the St. Gallen criteria.a more pure reﬂection of prognosis versus tamoxifen beneﬁt.
Additionally, the conﬂicting results may also partly be due to the
assay used for ER and PgR receptor assessment. In the Oxford
systematic review most tumours had been assessed with the
ligand-binding assay [1], while in our study all cases have been
analysed using standardized immunohistochemistry.
Also the scoring method might inﬂuence results. The different
composite scores are all somewhat differently calculated and the
most recent ASCO guideline warns of confusion across institutions
[4]. Moreover, with the current automated staining techniques,
oversaturated conditions to allow rapid reaction (about 30 min or
less) for antibodyeantigen binding lead to oversaturation on in-
tensity. In contrast to IHC4 [35,36], based on composite IHC score
(ER, PgR, HER2 and Ki67) we could identify patients at higher risk
for late recurrences. A possible explanation is that IHC4 used H-
score with three predeﬁned quartile cut-off points, but inaccuracy
due to oversaturation might also be an explanation.
Recently several authors reported on the capability of genomic
prognostic classiﬁers to provide information for late distant re-
currences after adjuvant therapy [36e39]. Although only the Breast
Cancer Index-linear [39] could add independent prognostic infor-
mation regarding the 10-year recurrence-free interval [36], all
described gene classiﬁers (EndoPredict, PAM50-ROR score, I/H-
ratio and BCI) offer additional signiﬁcant prognostic information
concerning the late recurrence-risk, beyond the clinicalepatho-
logical predictors [36e39]. Additionally, none of the gene classiﬁers
did evaluate the levels of ER and PgR expression as predictors for
late recurrences. All these reports focus on the low-risk patients
and the intention to prevent those patients from overtreatment,
since they seem not to beneﬁt from additional, extended treatment.
In contrast, we report on the increased risk over time in the speciﬁc
ER-H patients. Moreover, this additional information is already
available for every patient without extra costs. And although mo-
lecular tests might be more accurate than expression levels of ER
and PgR, an assumption that still needs to be tested, we do see an
application of the cheap, additional information provided by hor-
mone receptor expression levels to guide therapy decisions, espe-
cially in areas of the world where availability of expensive
molecular tests is non-existent.
Several trials have been conducted to study the effect of
extended adjuvant endocrine treatment. Lately the ATLAS-trial and
the aTTom-trial reported modest beneﬁt of extending endocrine
therapy beyond ﬁve years in unselected populations of mainly
post-menopausal patients [40,41]. Two recent meta-analyses also
reported contradictory results [42,43]. Petrelli and co-workers
conclude that extended endocrine therapy an opportunity is for
ERþ breast cancer patients to reduce recurrence risk and mortality.
Al Mubarak and colleagues found no signiﬁcant reduction in
recurrence and all-cause death in unselected patients [43]. Some
possible explanations for the different conclusions are differences
in statistical methods (ﬁxed effect modelling was not feasible for Al
Mubarak; individual patient data was not available; the choice of
endpoint differs in the different studies, with locoregional recur-
rence versus distant recurrence). The large proportion ER or ER
unknown breast cancer patients in the aTTom trial, who were
excluded from the analyses by Petrelli could have biased the
conclusion of Al Mubarak. Furthermore, according to Petrelli the
subgroup beneﬁtting most are the postmenopausal, Nþ patients. It
might also be (partly) due to a different beneﬁcial effect in different
ERþ breast cancer subgroups. Unfortunately, still no means are
available to precisely identify the actual subgroup beneﬁtting. An
exploratory, retrospective analysis of the MA.17 data showed an
improvement in disease free survival due to extended adjuvant
endocrine treatment for patients with ERþ/PgRþ tumours and not
for patients with ERþ/PgR tumours [44]. Furthermore, Dowsett
Table 3
Hazard ratios (95% conﬁdence intervals) and concordance indices for Cox proportional hazards models for the 6 alternative deﬁnitions of incomplete and high responsive
groups. Themodels contain the response deﬁnition (ER-I vs. ER-H), treatment group (control vs. tamoxifen), tumour grade, HER2-status, age, and their interaction. The column
Chi sq gives the log likelihood chi-square of the models. The cohort is restricted to node positive patients with RFI censored at 4 years.
HR 95% CI Chi sq df p-value C-index
Deﬁnition 1 Tam-H Ref 3.27 1 0.07 0.682
ER  50% & PgR  75% Tam-I 1.7 (0.7e4.3)
Con-H 7.1 (2.1e23.8)
Con-I 2.9 (0.8e9.8)
Deﬁnition 2 Tam-H Ref 2.29 1 0.13 0.678
ER  50% & PgR  50% (current) Tam-I 1.3 (0.6e2.6)
Con-H 5.5 (1.9e16.1)
Con-I 2.2 (0.7e6.5)
Deﬁnition 3 Tam-H Ref 1.67 1 0.2 0.676
ER  50% & PgR  25% Tam-I 1.4 (0.7e2.9)
Con-H 4.9 (0.9e14.1)
Con-I 2.6 (0.9e7.7)
Deﬁnition 4 Tam-H Ref 2.16 1 0.14 0.678
ER  75% Tam-I 0.4 (0.1e1.7)
Con-H 2.1 (0.9e5.2)
Con-I 3.5 (1.2e10.3)
Deﬁnition 5 Tam-H Ref 0.82 1 0.37 0.667
ER  50% Tam-I 0.7 (0.2e2.9)
Con-H 2.3 (0.9e5.5)
Con-I 3.7 (1.2e10.8)
Deﬁnition 6 Tam-H Ref 1.63 1 0.2 0.677
ER  25% Tam-I 0.5 (0.1e3.4)
Con-H 2.2 (1.0e5.1)
Con-I 4.6 (1.3e15.9)
Tam-H ¼ highly endocrine responsive patients, treated with Tamoxifen; Tam-I ¼ incomplete endocrine responsive patients, treated with Tamoxifen; Con-H ¼ highly
endocrine responsive patients, untreated; Con-I ¼ incomplete endocrine responsive patients, untreated.
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more than double the risk of their cancer recurring between ﬁve
and ten years after surgery and ﬁve years of adjuvant hormone
therapy [20]. This is completely in line with our results. This shift in
the relative risk of recurrence in ER-H patients may have biologic
and therapeutic relevance. Our data support the hypothesis that
patients with ER-H tumours might be candidates for prolonged
treatment. Therefore, wewould like to encourage the authors of the
NSABP B-14 trial [45] and of the extended adjuvant endocrine
therapy trials [40,41] to perform a subset analysis based on the St.
Gallen classes to conﬁrm our results.
Furthermore, the best cut-off of ER and PgR levels for endocrine
response classes appears to be deﬁnition 1 (ER  50%; PgR  75%).Table 4
Landmark analyses hazard ratios (90% conﬁdence intervals) for the Cox proportional haz
grade, HER2 status and age and stratifying for nodal status. Time is divided into four perio
period, and patients without events are censored at the end of each period. (Note: deﬁn
0e2
Deﬁnition 1 ER-I vs ER-H (all patients) 1.7 (0
ER  50% & PgR 75% Con vs Tam (all patients) 1.3 (0
ER-I vs ER-H (Tam. treated) 2.0 (0
Deﬁnition 2 ER-I vs ER-H (all patients) 2.2 (0
ER  50% & PgR  50% (current) Con vs Tam (all patients) 1.2 (0
ER-I vs ER-H (Tam. treated) 2.4 (0
Deﬁnition 3 ER-I vs ER-H (all patients) 1.9 (0
ER  50% & PgR 25% Con vs Tam (all patients) 1.3 (0
ER-I vs ER-H (Tam. treated) 2.7 (0
Deﬁnition 4 ER-I vs ER-H (all patients) 1.5 (0
ER  75% Con vs Tam (all patients) 1.2 (0
ER-I vs ER-H (Tam. treated) 0.9 (0
Deﬁnition 5 ER-I vs ER-H (all patients) 2.2 (0
ER  50% Con vs Tam (all patients) 1.1 (0
ER-I vs ER-H (Tam. treated) 1.5 (0
Deﬁnition 6 ER-I vs ER-H (all patients) 2.5 (0
ER  25% Con vs Tam (all patients) 1.1 (0
ER-I vs ER-H (Tam. treated) 1.1 (0
Tam ¼ tamoxifen treated; Con ¼ control group/untreated patients; ER-H ¼ highly end
N ¼ non-endocrine responsive patients.Although none of the deﬁnitions differed statistical signiﬁcantly
from deﬁnition 2, deﬁnition 1 showed a trend towards providing
the most pronounced separation of the survival curves with a
distinct decline for the ER-H curve after six years (Fig. S2). However,
the maximum C-index difference is very limited (0.667 versus
0.682) and it is unclear whether this is clinically relevant. Within
HRþ patients these cut-off values best divided patients into two
groups with intermediate or excellent tamoxifen-beneﬁt during
treatment. Stendahl et al. found the same cut-off level for PgR to be
most predictive for tamoxifen beneﬁt in a series of 500 premeno-
pausal patients [46]. Though, our results show a marked variability
in therapy sensitivity in HRþ breast cancer patients, the reviewed
cut-off values should only be hypothesis generating and anard models for the 6 alternative St. Gallen deﬁnitions including treatment, tumour
d, patients are only included in a section if they are recurrence free at the start of that
ition 2 is the current deﬁnition.)
years 2e4 years 4e6 years 6-Inf years
.6e5.2) 0.9 (0.4e2) 0.4 (0.2e1.1) 0.4 (0.2e0.9)
.5e3.1) 2.5 (1.3e4.6) 6.5 (2.8e15) 0.5 (0.1e1.8)
.6e7.1) 1.1 (0.4e2.8) 0.7 (0.1e3.5) 0.4 (0.2e0.9)
.8e6) 0.7 (0.4e1.4) 0.5 (0.2e1.3) 0.6 (0.3e1.3)
.5e2.9) 2.5 (1.3e4.7) 6.4 (2.8e14.9) 0.5 (0.1e1.7)
.8e7.4) 0.6 (0.3e1.4) 1.1 (0.2e5.7) 0.5 (0.2e1.2)
.8e5) 0.8 (0.4e1.6) 0.7 (0.3e1.7) 0.7 (0.3e1.4)
.5e3) 2.5 (1.3e4.6) 6.1 (2.7e14) 0.5 (0.1e1.6)
.9e8.2) 0.7 (0.3e1.6) 1.4 (0.3e6.8) 0.6 (0.3e1.3)
.5e4.1) 0.7 (0.2e2) 0.6 (0.1e2.6) 1.0 (0.3e3.6)
.5e2.9) 2.5 (1.4e4.7) 6.1 (2.7e13.8) 0.4 (0.1e1.6)
.2e3.8) 0.6 (0.1e2.4) 1.0 (0.1e8.6) 1.5 (0.4e5.2)
.8e6.1) 0.5 (0.1e2) 0.8 (0.2e3.5) 1.1 (0.2e4.8)
.4e2.6) 2.6 (1.4e4.9) 6.0 (2.6e13.8) 0.4 (0.1e1.6)
.3e6.4) 0.5 (0.1e3.4) 1.7 (0.2e15.3) 1.6 (0.4e7.2)
.8e8) 0.0 (0eInf) 0.7 (0.1e5.6) 1.5 (0.3e6.9)
.4e2.6) 2.6 (1.4e4.8) 5.9 (2.6e13.3) 0.4 (0.1e1.5)
.1e8.4) 0.0 (0eInf) 2.2 (0.2e22.2) 2.3 (0.5e10.9)
ocrine responsive patients; ER-I ¼ incomplete endocrine responsive patients; ER-
R.H.T. Koornstra et al. / The Breast 24 (2015) 705e712 711incentive for other authors to investigate the cut-off levels of the St.
Gallen response classes.
Currently, IHC staining and scoring for hormone receptor status
is standardized, in order to optimize the prognostic and predictive
value [4,5,47]. However, a dichotomous technique completely ne-
glects the variable treatment sensitivity of ERþ tumours. Subse-
quently, a second step in treatment decision-taking can be
considered after the simple dichotomous determination of hor-
mone receptor status, namely the classiﬁcation conform the St.
Gallen response classes in order to decide on duration. Extended
endocrine treatment in all ERþ breast cancer patients with tu-
mours expressing higher PgR levels can than be considered.
Our study has several limitations. First of all, sufﬁcient tumour
material was available from only 646 patients, and only 511 HRþ
patients. However, this subgroup was comparable to the total
original study population (data not shown). Furthermore, the time
on tamoxifen therapy is, with a median duration of 13 months, less
then the current standard of 5 years. However, we hypothesize that
our results can be extrapolated over time, based on the results of
Dowsett et al. and the observation that the increased recurrence
risk occurs after treatment cessation [20]. Next, it is not clear
whether our results also apply for aromatase inhibitor based
therapy. And although our results are considered to mainly reﬂect
intrinsic tumour biology rather than a speciﬁc treatment effect, it
has to be determinedwhether our data can also be reproducedwith
an aromatase inhibitor treatment.
In conclusion, we have shown a marked variability in therapy
sensitivity within the group of patients with HRþ breast tumours.
Patients with ER-H tumours have an increased tamoxifen beneﬁt
during therapy and in the ﬁrst years after completion of adjuvant
tamoxifen, but suffer from late recurrences. We propose that these
patients may beneﬁt from prolonged endocrine treatment.
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